SCHEMBL6718318

SCHEMBL6718318

Cc1ccccc1N(C(=O)C1CCCCC1)N(C(N)=S)c1ccccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.41
LMNA P02545 1/20 0.40
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
P2RX7 Q99572 2/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
NPC1 O15118 2/20 0.35
TSHR P16473 1/20 0.34
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
GAA P10253 1/20 0.33
CYP2C19 P33261 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6719625 0.86 OPRM1 (0.39) OPRM1LMNAP2RX7MEN1KMT2A
SCHEMBL6726655 0.84 IDH1 (0.38) OPRM1LMNATSHR
SCHEMBL6719441 0.82 OPRM1 (0.38) OPRM1LMNAP2RX7MEN1KMT2A
SCHEMBL6717391 0.81 LMNA (0.38) OPRM1LMNAMEN1KMT2ANPC1
SCHEMBL6722821 0.80 NPC1 (0.41) OPRM1LMNAMEN1KMT2ANPC1
SCHEMBL6722876 0.78 ALDH1A1 (0.39) OPRM1LMNAMEN1KMT2ANPC1
SCHEMBL6714072 0.78 NR1H4 (0.41) OPRM1LMNAP2RX7MEN1KMT2A
SCHEMBL6718458 0.76 ALDH1A1 (0.42) OPRM1MEN1KMT2ANPC1ALDH1A1
SCHEMBL6713841 0.76 HSD17B10 (0.39) LMNAMEN1KMT2ANPC1TSHR
SCHEMBL5089861 0.72 LMNA (0.54) OPRM1LMNAP2RX7MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 OPRM1 719/4885LMNA 3809/4885DDB1 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.